← Browse by Condition
Medical Condition
high grade serous ovarian carcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 1, Phase 2
NCT06799065 Phase 1
Recruiting
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Enrollment
90 pts
Location
United States
Sponsor
Accent Therapeutics
NCT07115043 Phase 1, Phase 2
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Enrollment
60 pts
Location
United States, Austr...
Sponsor
AstraZeneca